Advancements

• Technology developed to a lead compound of synthetic molecules that can be mass produced
• Technology published in multiple leading peer-reviewed journals
• Leading academic and development partners
• Strong and expanding patent portfolio
• Phase I trial designed
• Favorable Pre-IND meeting with FDA
• ~$5 million received to date in grant and equity funding

Next Steps

• Final animal studies
• Phase I and II clinical trials